Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival...
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
SAGE Publishing
2023-06-01
|
| Edice: | Therapeutic Advances in Medical Oncology |
| On-line přístup: | https://doi.org/10.1177/17588359231175440 |